Union européenne - français - EMA (European Medicines Agency)

janssen-cilag international n.v.    - amivantamab - carcinome, poumon non à petites cellules - agents antinéoplasiques - rybrevant as monotherapy is indicated for treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating epidermal growth factor receptor (egfr) exon 20 insertion mutations, after failure of platinum-based chemotherapy.

Canada - français - Health Canada

pfizer canada ulc - elranatamab - solution - 44mg - elranatamab 44mg

Canada - français - Health Canada

pfizer canada ulc - elranatamab - solution - 76mg - elranatamab 76mg

Canada - français - Health Canada

incyte corporation - tafasitamab - poudre pour solution - 200mg - tafasitamab 200mg - antineoplastic agents

Union européenne - français - EMA (European Medicines Agency)

incyte biosciences distribution b.v. - tafasitamab - lymphoma, large b-cell, diffuse - agents antinéoplasiques - minjuvi is indicated in combination with lenalidomide followed by minjuvi monotherapy for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) who are not eligible for autologous stem cell transplant (asct).

Canada - français - Health Canada

gilead sciences canada inc - sacituzumab govitécan - poudre pour solution - 180mg - sacituzumab govitécan 180mg - antineoplastic agents

Canada - français - Health Canada

janssen inc - amivantamab - solution - 350mg - amivantamab 350mg

Canada - français - Health Canada

kyowa kirin, inc. - mogamulizumab - solution - 4mg - mogamulizumab 4mg

Union européenne - français - EMA (European Medicines Agency)

swedish orphan biovitrum ab - loncastuximab tesirine - lymphoma, large b-cell, diffuse; lymphoma, b-cell - agents antinéoplasiques - zynlonta as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl), after two or more lines of systemic therapy.

Canada - français - Health Canada

janssen inc - téclistamab - solution - 30mg - téclistamab 30mg